DC-based Cancer Vaccines
Dendritic cells (DCs) are immune cells that capture and present antigens to T cells, initiating adaptive immune responses. JY BioMedical possesses a comprehensive tumor antigen library and can even further customize tumor antigens tailored to individual patients. We deliver tumor antigens to DCs, which then present these antigens to T cells or Gamma delta T cells, training them to specifically recognize tumor cells. We also utilize proprietary antibodies to directly bind to DC cells, enabling them to specifically target PDL1 or WT1. This process further enhances the ability to train immune cells, either in vivo or ex vivo, to recognize PDL1 or WT1, thereby promoting anti-tumor efficacy.The WT-1 protein is overexpressed in certain cancers, contributing to tumor growth by dysregulating cell proliferation. PD-L1, a protein on tumor cells, helps them evade the immune system by inhibiting T cell activity, leading to tumor progression and resistance to treatment.
What are dendritic cells (DCs)?
Dendritic cells (DCs) are a type of immune cell that play a critical role in the body’s defense system. They are specialized in capturing, processing, and presenting antigens to initiate and regulate immune responses.
Origin and Distribution
DCs originate in the bone marrow and travel through the bloodstream to various tissues and organs throughout the body. In peripheral tissues (such as the skin and mucosal surfaces), they exist in an immature state.
Antigen Capture and Processing
DCs have a high capacity for phagocytosis, allowing them to capture and internalize antigens from pathogens or other sources. They then process these antigens and prepare them for presentation.
Antigen Presentation
After processing antigens, DCs migrate to lymphoid organs (such as lymph nodes and the spleen) where they present the processed antigens to naive T cells. This interaction is crucial for initiating adaptive immune responses.
Maturation and Function
As DCs mature, they lose their antigen-capturing abilities and become fully functional antigen-presenting cells. Mature DCs are essential for activating T cells and coordinating the immune response.
Interact with Other Immune Cells
DCs also interact with B cells to enhance antibody production and with natural killer (NK) cells to boost their cytotoxic activity and production of interferon-γ (IFN-γ), further supporting the immune response.
Manufacturing of DC Cancer Vaccines
Applications of DC Cancer Vaccines
Our Existing Products
PDL1-Vax
DC-WT1
Role of WT-1 Protein in Cancer
Overexpression in Tumors
WT-1 is a key factor in Wilms’ tumor, a childhood kidney cancer, where it is overexpressed and serves as a disease marker. In leukemia (AML and ALL), WT-1 expression helps monitor disease progression and treatment response. WT-1 is also overexpressed in various solid tumors, including ovarian cancer, mesothelioma, and some types of breast cancer.
Interactions with Other Immune Cells
WT-1 functions as a transcription factor regulating genes involved in cell growth and differentiation. Its dysregulation can lead to uncontrolled cell proliferation, contributing to tumor development.
Inspiration
Impact Factor: 4.42
Role of PDL1 Protein in Cancer
Immune Checkpoint Regulation
PD-L1 is a ligand for the PD-1 receptor on T cells, and when they bind, it inhibits T cell activation, helping regulate the immune response and prevent excessive tissue damage. Tumors exploit this interaction by expressing PD-L1, which suppresses T cell activity, allowing the cancer cells to evade immune detection and grow unchecked. This immune evasion mechanism promotes tumor growth and spread.
Tumor Immune Evasion
Tumors expressing PD-L1 can create an immunosuppressive environment, enabling them to escape immune surveillance and avoid destruction by T cells, which promotes tumor growth and metastasis. Clinically, elevated PD-L1 levels are linked to poor prognosis and resistance to conventional therapies in cancers such as non-small cell lung cancer (NSCLC), melanoma, and bladder cancer.
PDL1-Vax Effectively Target/Destry Tumor Cells
Our Publication
Impact Factor: 6.13
